English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimer's disease mouse model

MPS-Authors
/persons/resource/persons182822

Kunath,  Nicolas
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (public)

srep11452.pdf
(Any fulltext), 2MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Kunath, N., van Groen, T., Allison, D. B., Kumar, A., Dozier-Sharpe, M., & Kadish, I. (2015). Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimer's disease mouse model. SCIENTIFIC REPORTS, 5: 11452. doi:10.1038/srep11452.


Cite as: http://hdl.handle.net/11858/00-001M-0000-0028-5533-6
Abstract
The orexigenic hormone ghrelin, a potential antagonist of the insulin system, ensures sufficient serum glucose in times of fasting. In the race for new therapeutics for diabetes, one focus of study has been antagonizing the ghrelin system in order to improve glucose tolerance. We provide evidence for a differential role of a ghrelin agonist on glucose homeostasis in an Alzheimer's disease mouse model fed a high-glycemic index diet as a constant challenge for glucose homeostasis. The ghrelin agonist impaired glucose tolerance immediately after administration but not in the long term. At the same time, the ghrelin agonist improved spatial learning in the mice, raised their activity levels, and reduced their body weight and fat mass. Immunoassay results showed a beneficial impact of long term treatment on insulin signaling pathways in hippocampal tissue. The present results suggest that ghrelin might improve cognition in Alzheimer's disease via a central nervous system mechanism involving insulin signaling.